- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
Saizen is a brand of recombinant human growth hormone (rhGH) used to treat endocrine and metabolic disorders. It is a synthetic version of the naturally occurring hormone produced in the body, and is used to treat growth failure in children and adults. Saizen is also used to treat adults with growth hormone deficiency, a condition in which the body does not produce enough growth hormone. It is also used to treat short stature associated with Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency.
Saizen is administered via subcutaneous injection, and is available in a variety of dosage forms, including pre-filled syringes, cartridges, and vials. It is also available in a variety of concentrations, including 5 mg, 8.8 mg, and 12 mg.
The Saizen market is highly competitive, with a number of companies offering products in this space. These include Merck KGaA, Pfizer, Novo Nordisk, Eli Lilly, and Sandoz. Show Less Read more